Volume 3, Issue 4 (Fall 2018)                   J Obstet Gynecol Cancer Res 2018, 3(4): 169-171 | Back to browse issues page

DOI: 10.30699/jogcr.3.4.30

XML Print

Abstract:   (1006 Views)

Background & Objective: Endometrial cancer is one of the most common gynecologic malignancies in developed countries. Survival rate in metastatic endometrial adenocarcinoma recurrence is reduced, and treatment in these patients is mostly palliative.  One of the therapeutic options in the endometrial adenocarcinoma recurrence is hormone therapy. The expected response to the hormonal treatment is about 10-20%.
Case Report: This is a case report from 57-year-old woman suffering from stage IA - Grade 1 endometrial cancer, who had vaginal carcinoma recurrence with liver and pulmonary metastasis 5.5 years after the initial treatment. Due to positive hormone receptor and the pathological profile of the tumor, hormone therapy with tamoxifen and megestrol was started. The treatment evaluation revealed complete response within five months with clearance of lung and liver metastatic lesions. There is no evidence of disease and metastases in the patientchr('39')s examination and imaging after 3 years of starting hormone therapy.
Conclusion: In the case of well-differentiated recurrent and metastatic endometrial cancer, good response to the hormone therapy by the least complications might be achieved.

Full-Text [PDF 206 kb]   (220 Downloads) |   |   Full-Text (HTML)  (200 Views)